Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Meghna Das, Thakur"'
Autor:
Neil H. Segal, Ignacio Melero, Victor Moreno, Neeltje Steeghs, Aurelien Marabelle, Kristoffer Rohrberg, Maria E. Rodriguez-Ruiz, Joseph P. Eder, Cathy Eng, Gulam A. Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C. Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H. Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label
Externí odkaz:
https://doaj.org/article/c7ab25df143a4df7a0b711f295ef7d2c
Autor:
Alberto Valdeolivas, Bettina Amberg, Nicolas Giroud, Marion Richardson, Eric J. C. Gálvez, Solveig Badillo, Alice Julien-Laferrière, Demeter Túrós, Lena Voith von Voithenberg, Isabelle Wells, Benedek Pesti, Amy A. Lo, Emilio Yángüez, Meghna Das Thakur, Michael Bscheider, Marc Sultan, Nadine Kumpesa, Björn Jacobsen, Tobias Bergauer, Julio Saez-Rodriguez, Sven Rottenberg, Petra C. Schwalie, Kerstin Hahn
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-16 (2024)
Abstract The consensus molecular subtypes (CMS) of colorectal cancer (CRC) is the most widely-used gene expression-based classification and has contributed to a better understanding of disease heterogeneity and prognosis. Nevertheless, CMS intratumor
Externí odkaz:
https://doaj.org/article/d6bdaa8d602c4df587d26a3ae4c61323
Autor:
Enriqueta Felip, Hiroshi Tanaka, Silvia Novello, Hao Xu, Heather Wakelee, Barbara Gitlitz, Martin Reck, Wei Zou, Elizabeth Bennett, Mark McCleland, Caicun Zhou, Satoshi Oizumi, Anna Kryzhanivska, Virginia McNally, Marcus Ballinger, Meghna Das Thakur, Steven L McCune, John Hamm, Minu K Srivastava, Nasser Altorki, Rüdiger Liersch
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Tumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA SP263 and Dako 22C3) for identification of PD-L1 patient subgroups (negative, positive, low,
Externí odkaz:
https://doaj.org/article/cfe63add9cfe46b48a019fc54672b05f
Autor:
Eugene Kim, Federico Cappuzzo, Martin Reck, Wei Zou, Mark A Socinski, Mark McCleland, Makoto Nishio, Stefanie Morris, David Shames, Meghna Das Thakur, Tony SK Mok, Howard Jack West, Robert M Jotte, Geetha Shankar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background The efficacy of atezolizumab (A) and/or bevacizumab (B) with carboplatin/paclitaxel (CP) chemotherapy was explored in the phase III, randomized IMpower150 study in patients with non-squamous non-small cell lung cancer (NSCLC) according to
Externí odkaz:
https://doaj.org/article/9361ce1aa5b1491d8d0d29d0d749e10c
Autor:
Anneleen Daemen, Akshata R. Udyavar, Thomas Sandmann, Congfen Li, Linda J. W. Bosch, William O’Gorman, Yijin Li, Amelia Au-Yeung, Chikara Takahashi, Omar Kabbarah, Richard Bourgon, Priti Hegde, Carlos Bais, Meghna Das Thakur
Publikováno v:
PLoS ONE, Vol 16, Iss 12 (2021)
Background Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with a 5% 5-year survival rate for metastatic disease, yet with limited therapeutic advancements due to insufficient understanding of and inability to accurately capture
Externí odkaz:
https://doaj.org/article/ceb3d9ff0113422f8fd18c42ca9291dd
Autor:
Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, David S. Shames, Meghna Das Thakur, Jane Shi, Lorna Bailey, Shweta Vadhavkar, Xian He, Wei Zhang, René Bruno
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 6, Pp n/a-n/a (2020)
Abstract We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs
Externí odkaz:
https://doaj.org/article/e89b5559af7e4b42a15cf0069035da3c
Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment
Publikováno v:
Radiology Case Reports, Vol 13, Iss 4, Pp 882-885 (2018)
Immune checkpoint inhibitors are increasingly used in treatment of metastatic renal cell carcinoma, melanoma, and nonsmall cell lung cancer, as well as in clinical trials for novel targets. We present a pediatric patient with metastatic alveolar soft
Externí odkaz:
https://doaj.org/article/752cc6f3caa544ff8933491bd6f71599
Autor:
Meghna Das, Thakur, Carl J, Franz, Laura, Brennan, Jurriaan, Brouwer-Visser, Rachel, Tam, Konstanty, Korski, Hartmut, Koeppen, James, Ziai, Galina, Babitzki, Dominique, Ranchere-Vince, Alexandre, Vasiljevic, Frédérique, Dijoud, Perrine, Marec-Bérard, Isabelle, Rochet, Michael A, Cannarile, Aurélien, Marabelle
Publikováno v:
European Journal of Cancer. 170:179-193
The clinical development of immune checkpoint-targeted immunotherapies has been disappointing so far in paediatric solid tumours. However, as opposed to adults, very little is known about the immune contexture of paediatric malignancies.We investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5c58d3a040b268045f4a933669361f
https://doi.org/10.1016/j.ejca.2022.03.012
https://doi.org/10.1016/j.ejca.2022.03.012
Autor:
Keiran S.M. Smalley, Hussein Tawbi, Darrin Stuart, Geoffrey T. Gibney, Sarah Sloot, Friedegund Meier, John M. Kirkwood, Uma N. Rao, Alejandro Villagra, Elena B. Pasquale, Jane L. Messina, Vernon K. Sondak, Keith T. Flaherty, Hensin Tsao, Jobin K. John, Inna V. Fedorenko, John M. Koomen, Bin Fang, Meghna Das Thakur, Kim H.T. Paraiso
Supplemental Figure 1. Characterization of the resistant cell lines. Supplemental Figure 2. Quantification of the cell invasion from figure 1D. Supplemental Figure 3. Model showing ligand dependent and independent ephrin signaling. Supplemental Figur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dce9c47489ab84a6f2137134ee8395f
https://doi.org/10.1158/2159-8290.22530725
https://doi.org/10.1158/2159-8290.22530725
Autor:
Peiyin Wang, Liping L. Sun, Robyn Clark, Maria Hristopoulos, Cecilia P.C. Chiu, Michael Dillon, WeiYu Lin, Amy A. Lo, Sreedevi Chalsani, Meghna Das Thakur, Kristin M. Zimmerman Savill, Lionel Rougé, Patrick Lupardus, Robert Piskol, Bushra Husain, Diego Ellerman, Vittal Shivva, Steven R. Leong, Meric Ovacik, Klara Totpal, Yan Wu, Christoph Spiess, Genee Lee, Douglas D. Leipold, Andrew G. Polson
Publikováno v:
Molecular Cancer Therapeutics. 21:974-985
New therapeutics and combination regimens have led to marked clinical improvements for the treatment of a subset of colorectal cancer. Immune checkpoint inhibitors have shown clinical efficacy in patients with mismatch-repair–deficient or microsate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5e4fea78c5f0d83f78a211e4a588405
https://doi.org/10.1158/1535-7163.mct-21-0599
https://doi.org/10.1158/1535-7163.mct-21-0599